Navigation Links
U.S. Food and Drug Administration Extends Review Timeline for BRILINTA (Ticagrelor) New Drug Application
Date:9/15/2010

WILMINGTON, Del., Sept. 15 /PRNewswire/ -- AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has extended the time to complete its review of the New Drug Application (NDA) for ticagrelor (BRILINTA).

(Logo: http://photos.prnewswire.com/prnh/20091027/PH99766LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO)

Accordingly, the FDA extended the Prescription Drug User Fee Act (PDUFA) date from September 16, 2010 to December 16, 2010. AstraZeneca will continue to work closely with the FDA to support the review of the ticagrelor NDA.

Ticagrelor is currently under regulatory review in nine additional territories around the world, including the European Union, Canada, and Brazil.

NOTES TO EDITORS:

ABOUT BRILINTA/BRILIQUE

Ticagrelor (BRILINTA/BRILIQUE) is an investigational oral antiplatelet treatment for Acute Coronary Syndromes (ACS). Ticagrelor is a direct-acting P2Y12 receptor antagonist in a chemical class called cyclo-pentyl-triazolo-pyrimidines (CPTPs). Ticagrelor is the first reversibly-binding oral ADP receptor antagonist.

BRILINTA and BRILIQUE are trademarks of the AstraZeneca group of companies.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. In the United States, AstraZeneca is a $14.8 billion dollar healthcare business.

For more information about AstraZeneca in the US or the AZ&Me™ Prescription Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363).


'/>"/>
SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market
2. Americans to U.S. Food and Drug Administration: Preserve Life-Saving Medicines; Reduce Antibiotic Use in Food Animal Production
3. Veterans Administration Health Care System Purchases 15 Zargis Cardioscan Systems
4. American Heart Association Comment: Advisory Committee Recommends that U.S. Food and Drug Administration Keep Rosiglitazone (Avandia) on the Market, Continue Clinical Trial of Safety and Efficacy
5. Sperian Respiratory Protection USA Awarded a 65,000 Reusable Respirator Order by the Veterans Health Administration
6. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
7. Kun Run Biotechnology Announces That They Have Obtained the Manufacturing Approval for Entecavir from the China State Food and Drug Administration
8. Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP
9. FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD
10. Federal Aviation Administration Selects Partners For Nationwide AED Program
11. Chinese State Food and Drug Administration Approves Company Facility for Producing Solid Dosage Perindopril
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Südkorea, 23. Februar 2017 LG ... für Sterilisationsaufgaben vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache des ... ultraviolette Strahlung im Bereich zwischen 200 und 280 nm und ... von Bakterien, indem es ihre DNA zerstört. Das Produkt ... ...
(Date:2/23/2017)... -- Im Rahmen seiner Schlüsselwachstumsstrategie arbeitet die ... chinesischen Provinz Guizhou, 2017 mit dem Angebot von Anreize schaffenden ... Entwicklung einer eingebetteten Hightech-Schlüsselindustrie. Foto - http://mma.prnewswire.com/media/471342/First_CRH__CHina_Railway_High_Speed__Train_Enters_Guian.jpg ... ... ...
(Date:2/23/2017)... York , February 23, 2017 ... arising from increasing caseload for varicose veins in their ... the globe are prompting the adoption of endovenous laser ... on global endovenous laser therapy market, published ... aftereffects of lifestyle choices and consequences of obesity have ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... ... In the Health Care IT campaign, Robert Herjavec discusses health IT security ... will be attacked, but when.” However, he and many others involved highlight a promising ... in auditing and monitoring have taken security in health care a very long way. ...
(Date:2/24/2017)... ... February 24, 2017 , ... With ProGlass Prism users now have ... Users have total control over position, rotation, distortion, edge softness, edge blur, chromatic aberration, ... Pro X. , With ProGlass Prism users are given the tools and effects ...
(Date:2/24/2017)... ... , ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer recently ... as the Chairman of the Management Committee when IFN was originally formed in 2002 ... of investor/owners and development of the business plan. He became the first paid ...
(Date:2/24/2017)... ... February 24, 2017 , ... Castle ... hosted their Military Wedding Giveaway, with the winning couple announced on Feb. 14, ... services generously donated from local vendors: A Matter of Taste, Ryan Rousseau Enterprises, ...
(Date:2/23/2017)... Miami, FL (PRWEB) , ... February 23, 2017 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – will return to the La Gorce Country Club in Miami Beach ...
Breaking Medicine News(10 mins):